NCT05935085Phase 2Terminated

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

Study sponsor: AnaptysBio, Inc. · ANAB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-10-16Actual
Enrollment · participants201Actual
Source updated2025-02-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview